NEU 2.81% $18.65 neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-179

  1. 5,763 Posts.
    lightbulb Created with Sketch. 309


    An aquirer will likely have many other parts. So the exposure for Neurens assets would be highly diluted if a current shareholder invested in the aquirer.

    Thus it would`t be effective. IMO

    Best to get the maximum possible when/if TO occurs. Not good enough offer, send `em packing.

    It will really depend if there is more than 1 suitor.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.